PeptideDB

Cabamiquine succinate (DDD107498 succinate; DDD-498 succinate; M5717 succinate) 2444781-71-7

Cabamiquine succinate (DDD107498 succinate; DDD-498 succinate; M5717 succinate) 2444781-71-7

CAS No.: 2444781-71-7

Cabamiquine (DDD107498) succinate is a potent, orally bioavailable antimalarial agent that can inhibit multiple stages o
Data collection:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Cabamiquine (DDD107498) succinate is a potent, orally bioavailable antimalarial agent that can inhibit multiple stages of the parasite life cycle, with EC50 of 1 nM against P. falciparum 3D7. Cabamiquine succinate inhibits protein synthesis by targeting eEF2/CaMKIII, with EC50 of 2 nM for WT-PfeEF2.

Physicochemical Properties


Molecular Formula C31H37FN4O6
Molecular Weight 580.6471
Exact Mass 580.269
CAS # 2444781-71-7
Related CAS # Cabamiquine;1469439-69-7
PubChem CID 138319698
Appearance White to off-white solid powder
Hydrogen Bond Donor Count 3
Hydrogen Bond Acceptor Count 10
Rotatable Bond Count 10
Heavy Atom Count 42
Complexity 739
Defined Atom Stereocenter Count 0
SMILES

FC1C([H])=C([H])C2=C(C=1[H])C(=C([H])C(C1C([H])=C([H])C(=C([H])C=1[H])C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H])=N2)C(N([H])C([H])([H])C([H])([H])N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H])=O.O([H])C(C([H])([H])C([H])([H])C(=O)O[H])=O

InChi Key OTKHBNSZSWWVRJ-UHFFFAOYSA-N
InChi Code

InChI=1S/C27H31FN4O2.C4H6O4/c28-22-7-8-25-23(17-22)24(27(33)29-9-12-31-10-1-2-11-31)18-26(30-25)21-5-3-20(4-6-21)19-32-13-15-34-16-14-32;5-3(6)1-2-4(7)8/h3-8,17-18H,1-2,9-16,19H2,(H,29,33);1-2H2,(H,5,6)(H,7,8)
Chemical Name

butanedioic acid;6-fluoro-2-[4-(morpholin-4-ylmethyl)phenyl]-N-(2-pyrrolidin-1-ylethyl)quinoline-4-carboxamide
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light.
Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets CaMK III Plasmodium
ln Vitro Camiquine succinate (24–48 hours) disrupts protein synthesis, produces irregularities in trophozoites, and prevents the formation of trophozoites and fragmented aggregates in the parasite [1]. With EC50 = 1.0 nM, EC90 = 2.4 nM, and EC99 = 5.9 nM against 3D7 parasites, carbaquine succinate exhibits good efficacy[1]. When coupled with hepatocytes or liver microsomes, camelquin succinate shows good metabolic stability [1].
ln Vivo Cabamiquine (DDD107498) exhibits an ED90 of 0.57 mg/kg after a single oral dose in mice infected with the rodent parasite P. berghei[1].
References

[1]. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature. 2015 Jun 18;522(7556):315-20.

[2]. Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy. J Med Chem. 2016 Nov 10;59(21):9672-9685.


Solubility Data


Solubility (In Vitro) DMSO : 135 mg/mL (232.50 mM)
Solubility (In Vivo) Solubility in Formulation 1: ≥ 2.25 mg/mL (3.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.25 mg/mL (3.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

Solubility in Formulation 3: ≥ 2.25 mg/mL (3.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.7222 mL 8.6110 mL 17.2221 mL
5 mM 0.3444 mL 1.7222 mL 3.4444 mL
10 mM 0.1722 mL 0.8611 mL 1.7222 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.